Related references
Note: Only part of the references are listed.Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
F. -C. Bidard et al.
ANNALS OF ONCOLOGY (2010)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh et al.
BRITISH JOURNAL OF CANCER (2010)
Bevacizumab in the treatment of breast cancer
Angelos K. Koutras et al.
CANCER TREATMENT REVIEWS (2010)
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
Lokesh Jain et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer
Jean-Louis Formento et al.
PHARMACOGENOMICS (2009)
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an eastern cooperative oncology group study
Afshin Dowlati et al.
CLINICAL CANCER RESEARCH (2008)
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Harold J. Burstein et al.
CLINICAL CANCER RESEARCH (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Steven J. Harper et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS
R. Zhai et al.
THORAX (2007)
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer
AM Jubb et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Association of genetic polymorphisms in the VEGF gene with breast cancer survival
H Lu et al.
CANCER RESEARCH (2005)
Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis
QR Jin et al.
CLINICAL CANCER RESEARCH (2005)
A Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
KD Miller et al.
CLINICAL CANCER RESEARCH (2005)
Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer
KT Ku et al.
ORAL ONCOLOGY (2005)
Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer
SJ Lee et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci
YY Shi et al.
CELL RESEARCH (2005)
VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer
MI Koukourakis et al.
LUNG CANCER (2004)
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk
P Krippl et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels
W Renner et al.
JOURNAL OF VASCULAR RESEARCH (2000)
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production
CJ Watson et al.
CYTOKINE (2000)
Share Paper
